Articles related to ALZHEIMER'S/DEMENTIA

Changes to blood-based biomarkers can be detected before Alzheimer’s symptoms appear, potentially allowing for earlier intervention and more targeted treatment approaches.

Zunveyl, a prodrug of galantamine, has been formulated to minimize gastrointestinal absorption, potentially addressing common tolerability issues associated with acetylcholinesterase inhibitors in Alzheimer’s treatment.

LANS presents with memory symptoms that mimic Alzheimer’s disease, but brain imaging and biomarkers indicate a different underlying condition, potentially leading to more accurate diagnoses and prognoses for older adults with cognitive decline.

Kisunla’s approval introduces a novel treatment option for early Alzheimer’s disease, potentially altering the landscape of AD management with its ability to significantly reduce amyloid plaque levels and slow cognitive decline.

Recent research suggests that promoting neuroplasticity through various techniques may offer new treatment possibilities for patients with neurodegenerative diseases, developmental disorders, and mental health conditions.

This study reveals that individuals with autosomal dominant Alzheimer’s disease who are heterozygous for the APOE3 Christchurch variant experience a median delay in cognitive impairment onset of approximately five years compared to those without the variant.